
Keywords: پلی تترافلورو اتیلن; FDA; U.S. Food and Drug Administration; iPSC; Induced Pluripotent Stem Cell; MSC; Mesenchymal Stem Cell; POZNAN; Percutaneous Transvenous Transplantation of Autologous Myoblasts in the Treatment of Postinfarction Heart Failure; PTFE; polytetrafluoroethyle